Posted: 30 August 2022 Cloud services can be enablers for a company’s digital transformation. However, understanding the risks and legal issues associated with using cloud services is critical for risk management and protection of an organisation’s data and IP and to…
Posted: 26 August 2022 Today Patrys announced that the Olivia Newton-John Cancer Research Institute (ONJCRI) has been awarded a $100,000 Victorian State Government Victorian Medical Research Acceleration Fund (VMRAF) grant to support its research investigating the potential for PAT-DX1…
Posted: 25 August 2022 Closing date: 31 August 2022 Translational Manufacturing@TRI (TM@TRI) will serve as Australia’s first purpose built biomedical translational manufacturing facility that will enable biotech and medtech start-up companies to move to the scale-up stage. Construction…
Posted: 24 August 2022 The Directors of Biotron Limited (‘Biotron’ or ‘the Company’) are pleased to advise that a Phase 2 HIV-1 clinical trial (BIT225-010; ACTRN12621000937819) of its lead antiviral drug, BIT225, is fully recruited. The trial, which…
Posted: 18 August 2022 Dimerix Limited (ASX: DXB) a biopharmaceutical company with Phase 3 clinical studies in inflammatory diseases currently underway, today confirmed that the CLARITY 2.0 led study of COVID-19 patients has concluded recruitment to allow this…
Posted: 15 August 2022 Patience pays off in the biotech world, but the June quarter was pretty fast-moving for a clutch of Australian companies as trials yielded results, patents and manufacturing deals were inked and the odd acquisition…
Posted: 11 August 2022 PolyNovo Biomaterials Ltd. are delighted to share a new article published as part of the #YourSkin2022 campaign that discusses the innovative application of #NovoSorbBTM for skin cancer patients with complex reconstructive needs. A synthetic dermal…
Posted: 11 August 2022 CSIRO, Australia’s national science agency, has opened a new $23.1 million national lab in Melbourne that will bolster the nation’s ability to produce vaccines and drug treatments onshore. Researchers at CSIRO’s National Vaccine and…
Posted: 10 August 2022 Research Australia is pleased to partner with the Childhood Dementia Initiative to report on global childhood dementia clinical research: Childhood Dementia Global Landscape Analysis. Research Australia’s report identifies high value-research investment opportunities and emerging…
Posted: 9 August 2022 Genesis Capital is partnering with existing management to expand Crux into new testing and clinical trial streams. Crux Biolabs, a leading Australian laboratory for vaccines, immunotherapies, immuno-oncology and infectious diseases, has announced a significant…
Posted: 8 August 2022 Neuren Pharmaceuticals (ASX: NEU) today announced that its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome (PMS) and Pitt Hopkins syndrome (PTHS) are open for enrolment. The first subjects…
Posted: 4 August 2022 Burnet Institute, in collaboration with Monash Institute of Pharmaceutical Sciences (MIPS) has received Proof of Concept funding from BioCurate to develop next-generation human immunodeficiency virus (HIV) antivirals. The multi-disciplinary research team, led jointly by…